JP2012526530A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526530A5 JP2012526530A5 JP2012510274A JP2012510274A JP2012526530A5 JP 2012526530 A5 JP2012526530 A5 JP 2012526530A5 JP 2012510274 A JP2012510274 A JP 2012510274A JP 2012510274 A JP2012510274 A JP 2012510274A JP 2012526530 A5 JP2012526530 A5 JP 2012526530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- axl
- amino acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000003463 hyperproliferative effect Effects 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 claims 1
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 claims 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102100031638 Tuberin Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006909 anti-apoptosis Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09006355.3 | 2009-05-11 | ||
| EP09006355A EP2270053A1 (en) | 2009-05-11 | 2009-05-11 | Humanized AXL antibodies |
| EP09006474.2 | 2009-05-13 | ||
| EP09006474 | 2009-05-13 | ||
| PCT/EP2010/056487 WO2010130751A1 (en) | 2009-05-11 | 2010-05-11 | Humanized axl antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015188556A Division JP2016011306A (ja) | 2009-05-11 | 2015-09-25 | ヒト化ａｘｌ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526530A JP2012526530A (ja) | 2012-11-01 |
| JP2012526530A5 true JP2012526530A5 (enExample) | 2013-06-20 |
| JP5909442B2 JP5909442B2 (ja) | 2016-04-26 |
Family
ID=42272537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510274A Expired - Fee Related JP5909442B2 (ja) | 2009-05-11 | 2010-05-11 | ヒト化ａｘｌ抗体 |
| JP2015188556A Pending JP2016011306A (ja) | 2009-05-11 | 2015-09-25 | ヒト化ａｘｌ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015188556A Pending JP2016011306A (ja) | 2009-05-11 | 2015-09-25 | ヒト化ａｘｌ抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8841424B2 (enExample) |
| EP (1) | EP2430050A1 (enExample) |
| JP (2) | JP5909442B2 (enExample) |
| KR (1) | KR20120035145A (enExample) |
| CN (1) | CN102421802B (enExample) |
| AR (1) | AR076564A1 (enExample) |
| AU (1) | AU2010247464B2 (enExample) |
| BR (1) | BRPI1013428A2 (enExample) |
| CA (1) | CA2759836A1 (enExample) |
| IL (1) | IL216147A (enExample) |
| MX (1) | MX2011011825A (enExample) |
| RU (2) | RU2571224C2 (enExample) |
| TW (2) | TWI526223B (enExample) |
| WO (1) | WO2010130751A1 (enExample) |
| ZA (1) | ZA201107529B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR076564A1 (es) * | 2009-05-11 | 2011-06-22 | U3 Pharma Gmbh | Anticuerpos humanizados de axl(receptor de tirosina quinasa) |
| EP2483289B2 (en) | 2009-10-02 | 2025-03-26 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
| US9562252B2 (en) | 2011-05-13 | 2017-02-07 | Biogen Ma Inc. | Methods of preventing and removing trisulfide bonds |
| WO2012175691A1 (en) * | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
| AU2012273955A1 (en) * | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| KR102167228B1 (ko) * | 2012-11-05 | 2020-10-19 | 피에르 파브르 메디카먼트 | 새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도 |
| US9822347B2 (en) * | 2012-12-14 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy |
| EP3229836B1 (en) * | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016097370A2 (en) | 2014-12-18 | 2016-06-23 | Bergen Teknologioverføring As | Anti-axl antagonistic antibodies |
| GB201506411D0 (en) * | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| ES3063952T3 (en) * | 2015-05-18 | 2026-04-21 | Agensys Inc | Antibodies that bind to axl proteins |
| WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| CN110922481A (zh) | 2015-09-24 | 2020-03-27 | 第一三共株式会社 | 抗garp抗体 |
| EP4656204A3 (en) * | 2016-04-15 | 2026-06-03 | BioAtla, Inc. | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| GB201610902D0 (en) | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| CN109160941B (zh) * | 2018-09-29 | 2020-09-04 | 未名生物医药有限公司 | 蛋白序列17e11及其用途 |
| RU2678569C1 (ru) * | 2018-10-31 | 2019-01-30 | Гордейчук Владимир Евгеньевич | Способ подавления метастазирования опухолей |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| CN110982791A (zh) * | 2019-12-26 | 2020-04-10 | 百泰生物药业有限公司 | 一种分泌axl抗体的杂交瘤细胞的制备筛选方法 |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| US11807688B2 (en) * | 2020-02-28 | 2023-11-07 | Les Laboratoires Servier | Anti-AXL antibodies and compositions |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| WO2021204713A1 (en) | 2020-04-08 | 2021-10-14 | Bergenbio Asa | Axl inhibitors for antiviral therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| WO2022164288A1 (ko) | 2021-01-29 | 2022-08-04 | 한국과학기술원 | 비염증성 식세포작용 유도 활성을 갖는 융합분자 |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| CN115927243A (zh) * | 2022-09-13 | 2023-04-07 | 中山大学 | 一种akt1蛋白的抑制性磷酸化位点及其应用 |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931385A (en) * | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
| DE3900534A1 (de) | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| WO1997034636A1 (en) * | 1996-03-20 | 1997-09-25 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| EP1190061A1 (en) | 1999-06-07 | 2002-03-27 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2006037604A1 (en) | 2004-10-01 | 2006-04-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| EP1891110A2 (en) | 2005-06-07 | 2008-02-27 | Esbatech AG | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha |
| EP2170395A1 (en) | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| CA2703519C (en) * | 2007-11-09 | 2017-04-18 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| BRPI0820073A2 (pt) * | 2007-11-12 | 2015-06-23 | U3 Pharma Gmbh | Anticorpos anti-axl |
| AR076564A1 (es) * | 2009-05-11 | 2011-06-22 | U3 Pharma Gmbh | Anticuerpos humanizados de axl(receptor de tirosina quinasa) |
-
2010
- 2010-05-11 AR ARP100101604A patent/AR076564A1/es unknown
- 2010-05-11 KR KR1020117026757A patent/KR20120035145A/ko not_active Ceased
- 2010-05-11 CN CN201080020597.6A patent/CN102421802B/zh not_active Expired - Fee Related
- 2010-05-11 MX MX2011011825A patent/MX2011011825A/es active IP Right Grant
- 2010-05-11 US US13/320,060 patent/US8841424B2/en not_active Expired - Fee Related
- 2010-05-11 TW TW103142582A patent/TWI526223B/zh not_active IP Right Cessation
- 2010-05-11 JP JP2012510274A patent/JP5909442B2/ja not_active Expired - Fee Related
- 2010-05-11 AU AU2010247464A patent/AU2010247464B2/en not_active Ceased
- 2010-05-11 BR BRPI1013428A patent/BRPI1013428A2/pt not_active IP Right Cessation
- 2010-05-11 CA CA2759836A patent/CA2759836A1/en not_active Abandoned
- 2010-05-11 EP EP10718217A patent/EP2430050A1/en not_active Withdrawn
- 2010-05-11 WO PCT/EP2010/056487 patent/WO2010130751A1/en not_active Ceased
- 2010-05-11 TW TW099114946A patent/TW201105348A/zh unknown
- 2010-05-11 RU RU2011150183/10A patent/RU2571224C2/ru not_active IP Right Cessation
-
2011
- 2011-10-13 ZA ZA2011/07529A patent/ZA201107529B/en unknown
- 2011-11-03 IL IL216147A patent/IL216147A/en not_active IP Right Cessation
-
2014
- 2014-07-15 US US14/331,709 patent/US20150037323A1/en not_active Abandoned
-
2015
- 2015-09-25 JP JP2015188556A patent/JP2016011306A/ja active Pending
- 2015-11-03 RU RU2015147287A patent/RU2015147287A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015147287A (ru) | Гуманизированные антитела против axl | |
| JP2013531655A5 (enExample) | ||
| Hervent et al. | Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics | |
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| JP2008529489A5 (enExample) | ||
| JP2013165711A5 (enExample) | ||
| JP2018511319A5 (enExample) | ||
| JP2017532005A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| RU2010123888A (ru) | Axl-антитела | |
| JP2016536330A5 (enExample) | ||
| JP2018518151A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| EA201001874A1 (ru) | Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты | |
| JP2012012402A5 (enExample) | ||
| CN120365432A (zh) | 双特异性抗体 | |
| RU2013129450A (ru) | Способ лечения опухолей с применением vegf-специфических антагонистов | |
| He et al. | A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging | |
| AU2015238264A1 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer | |
| Field et al. | Novel highly specific anti‐periostin antibodies uncover the functional importance of the fascilin 1‐1 domain and highlight preferential expression of periostin in aggressive breast cancer | |
| US20250145708A1 (en) | Epitope of Regulatory T Cell Surface Antigen and Antibody Specifically Binding Thereto | |
| CN117062834A (zh) | Gpc3人源化抗体及其应用 | |
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| TWI688575B (zh) | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 | |
| CN108025064A (zh) | 抗磷脂酰肌醇蛋白聚糖-3抗体和其用于诊断与治疗癌症的用途 |